

# Jeri W Nieves

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1721755/publications.pdf>

Version: 2024-02-01

58  
papers

4,495  
citations

218592

26  
h-index

149623

56  
g-index

61  
all docs

61  
docs citations

61  
times ranked

3683  
citing authors

#	ARTICLE	IF	CITATIONS
1	Case-control study in ALS using the National ALS Registry: lead and agricultural chemicals are potential risk factors. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2022, 23, 190-202.	1.1	11
2	Teriparatide and pelvic fracture healing: a phase 2 randomized controlled trial. <i>Osteoporosis International</i> , 2022, 33, 239-250.	1.3	10
3	Effects of teriparatide and loading modality on modeling-based and remodeling-based bone formation in the human femoral neck. <i>Bone</i> , 2022, 157, 116342.	1.4	6
4	Metabolic Abnormalities, Dietary Risk Factors and Nutritional Management in Amyotrophic Lateral Sclerosis. <i>Nutrients</i> , 2021, 13, 2273.	1.7	25
5	Perspective: US Documentation and Regulation of Human Nutrition Randomized Controlled Trials. <i>Advances in Nutrition</i> , 2021, 12, 21-45.	2.9	13
6	Standard Versus Cyclic Teriparatide and Denosumab Treatment for Osteoporosis: A Randomized Trial. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 219-225.	3.1	15
7	Abnormal microarchitecture and stiffness in postmenopausal women with isolated osteoporosis at the 1/3 radius. <i>Bone</i> , 2020, 132, 115211.	1.4	6
8	Vertebral fracture assessment (VFA) for osteoporosis screening in US postmenopausal women: is it cost-effective?. <i>Osteoporosis International</i> , 2020, 31, 2321-2335.	1.3	16
9	No evidence for alteration in early secondary mineralization by either alendronate, teriparatide or combination of both in transiliac bone biopsy samples from postmenopausal osteoporotic patients. <i>Bone Reports</i> , 2020, 12, 100253.	0.2	5
10	Nutrition and Sarcopenia—What Do We Know?. <i>Nutrients</i> , 2020, 12, 1755.	1.7	152
11	Modeling-Based Bone Formation in the Human Femoral Neck in Subjects Treated With Denosumab. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 1282-1288.	3.1	30
12	Identification of prevalent vertebral fractures using Vertebral Fracture Assessment (VFA) in asymptomatic postmenopausal women: A systematic review and meta-analysis. <i>Bone</i> , 2020, 136, 115358.	1.4	14
13	Loading modality and age influence teriparatide-induced bone formation in the human femoral neck. <i>Bone</i> , 2020, 136, 115373.	1.4	5
14	Determining the Effects of a 4-Week Structured Strength and Flexibility Exercise Program on Functional Status of Subjects with Osteoporosis. <i>HSS Journal</i> , 2019, 15, 241-246.	0.7	3
15	Reply. <i>Gastroenterology</i> , 2019, 157, 586.	0.6	1
16	Dexlansoprazole and Esomeprazole Do Not Affect Bone Homeostasis in Healthy Postmenopausal Women. <i>Gastroenterology</i> , 2019, 156, 926-934.e6.	0.6	35
17	Administration of teriparatide for four years cyclically compared to two years daily in treatment Na <sup>+</sup> ve and alendronate treated women. <i>Bone</i> , 2019, 120, 246-253.	1.4	15
18	Evaluation of a Multimodal, Direct-to-Patient Educational Intervention Targeting Barriers to Osteoporosis Care: A Randomized Clinical Trial. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 763-772.	3.1	27

#	ARTICLE	IF	CITATIONS
19	Randomized phase 2 trial of monthly vitamin D to prevent respiratory complications in children with sickle cell disease. <i>Blood Advances</i> , 2018, 2, 969-978.	2.5	24
20	Improved fracture prediction using different fracture risk assessment tool adjustments in HIV-infected women. <i>Aids</i> , 2018, 32, 1699-1706.	1.0	26
21	THU0472â€¦Factors associated with readiness for adopting osteoporosis treatment change. , 2018, , .		0
22	THU0490â€¦Temporal increases in side effect concerns of osteoporosis medications among women with previous fractures. , 2018, , .		0
23	Results of a fracture liaison service on hip fracture patients in an open healthcare system. <i>Aging Clinical and Experimental Research</i> , 2017, 29, 331-334.	1.4	22
24	Sex-Differences in Skeletal Growth and Aging. <i>Current Osteoporosis Reports</i> , 2017, 15, 70-75.	1.5	27
25	Treatment Sequence Matters: Anabolic and Antiresorptive Therapy for Osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 198-202.	3.1	181
26	Regional Differences in Incident Pre frailty and Frailty. <i>Journal of Women's Health</i> , 2017, 26, 992-998.	1.5	2
27	Effects of Daily or Cyclic Teriparatide on Bone Formation in the Iliac Crest in Women on No Prior Therapy and in Women on Alendronate. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 1518-1526.	3.1	35
28	Increase in Fracture Risk Following Unintentional Weight Loss in Postmenopausal Women: The Global Longitudinal Study of Osteoporosis in Women. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 1466-1472.	3.1	29
29	A multi-modal intervention for Activating Patients at Risk for Osteoporosis (APROPOS): Rationale, design, and uptake of online study intervention material. <i>Contemporary Clinical Trials Communications</i> , 2016, 4, 14-24.	0.5	13
30	Association Between Dietary Intake and Function in Amyotrophic Lateral Sclerosis. <i>JAMA Neurology</i> , 2016, 73, 1425.	4.5	74
31	Lack of Evidence Linking Calcium With or Without Vitamin D Supplementation to Cardiovascular Disease in Generally Healthy Adults: A Clinical Guideline From the National Osteoporosis Foundation and the American Society for Preventive Cardiology. <i>Annals of Internal Medicine</i> , 2016, 165, 867.	2.0	84
32	Eating disorders, menstrual dysfunction, weight change and DMPA use predict bone density change in college-aged women. <i>Bone</i> , 2016, 84, 113-119.	1.4	15
33	Effect of Teriparatide on Bone Formation in the Human Femoral Neck. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 1498-1505.	1.8	33
34	Daily or Cyclical Teriparatide Treatment in Women With Osteoporosis on no Prior Therapy and Women on Alendronate. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 2769-2776.	1.8	33
35	Maximizing bone healthâ€”magnesium, BMD and fractures. <i>Nature Reviews Endocrinology</i> , 2014, 10, 255-256.	4.3	22
36	When, Where and How Osteoporosis-Associated Fractures Occur: An Analysis from the Global Longitudinal Study of Osteoporosis in Women (GLOW). <i>PLoS ONE</i> , 2013, 8, e83306.	1.1	63

#	ARTICLE	IF	CITATIONS
37	Atypical Subtrochanteric and Femoral Shaft Fractures and Possible Association with Bisphosphonates. <i>Current Osteoporosis Reports</i> , 2010, 8, 34-39.	1.5	77
38	Nutritional Factors That Influence Change in Bone Density and Stress Fracture Risk Among Young Female Cross-Country Runners. <i>PM and R</i> , 2010, 2, 740-750.	0.9	127
39	Nutritional therapies (including fosteum). <i>Current Osteoporosis Reports</i> , 2009, 7, 5-11.	1.5	7
40	The clinically meaningful change in physical performance scores in an elderly cohort. <i>Aging Clinical and Experimental Research</i> , 2007, 19, 484-491.	1.4	10
41	Effects Of a One-Month Treatment With PTH(1-34) on Bone Formation on Cancellous, Endocortical, and Periosteal Surfaces of the Human Ilium. <i>Journal of Bone and Mineral Research</i> , 2007, 22, 495-502.	3.1	219
42	Calcium and fracture risk. <i>American Journal of Clinical Nutrition</i> , 2007, 86, 1579-1580.	2.2	7
43	Osteoporosis: the role of micronutrients. <i>American Journal of Clinical Nutrition</i> , 2005, 81, 1232S-1239S.	2.2	243
44	A Novel Tetracycline Labeling Schedule for Longitudinal Evaluation of the Short-Term Effects of Anabolic Therapy With a Single Iliac Crest Bone Biopsy: Early Actions of Teriparatide. <i>Journal of Bone and Mineral Research</i> , 2005, 21, 366-373.	3.1	248
45	Daily and Cyclic Parathyroid Hormone in Women Receiving Alendronate. <i>New England Journal of Medicine</i> , 2005, 353, 566-575.	13.9	245
46	Evaluation of continuous summary physical performance scores (CSPPS) in an elderly cohort. <i>Aging Clinical and Experimental Research</i> , 2005, 17, 193-200.	1.4	11
47	Males Have Larger Skeletal Size and Bone Mass Than Females, Despite Comparable Body Size. <i>Journal of Bone and Mineral Research</i> , 2004, 20, 529-535.	3.1	245
48	Calcium, vitamin D, and nutrition in elderly adults. <i>Clinics in Geriatric Medicine</i> , 2003, 19, 321-335.	1.0	29
49	Anabolic Action of Parathyroid Hormone Is Skeletal Site Specific at the Tissue and Cellular Levels in Mice. <i>Journal of Bone and Mineral Research</i> , 2002, 17, 808-816.	3.1	129
50	Effects of Daily Treatment with Parathyroid Hormone on Bone Microarchitecture and Turnover in Patients with Osteoporosis: A Paired Biopsy Study*. <i>Journal of Bone and Mineral Research</i> , 2001, 16, 1846-1853.	3.1	580
51	Alendronate Does Not Block the Anabolic Effect of PTH in Postmenopausal Osteoporotic Women. <i>Journal of Bone and Mineral Research</i> , 1998, 13, 1051-1055.	3.1	108
52	Parathyroid Responsivity in Postmenopausal Women with Osteoporosis During Treatment with Parathyroid Hormone1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 788-790.	1.8	14
53	Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. <i>Lancet</i> , The, 1997, 350, 550-555.	6.3	713
54	Histomorphometric Assessment of Bone Mass, Structure, and Remodeling: A Comparison Between Healthy Black and White Premenopausal Women. <i>Journal of Bone and Mineral Research</i> , 1997, 12, 948-957.	3.1	78

#	ARTICLE	IF	CITATIONS
55	Resistance to Bone Resorbing Effects of PTH in Black Women. Journal of Bone and Mineral Research, 1997, 12, 958-966.	3.1	173
56	Oral 1,25-dihydroxyvitamin D administration in osteoporotic women: Effects of estrogen therapy. Journal of Bone and Mineral Research, 1995, 10, 594-600.	3.1	8
57	Bone structure in postmenopausal hyperparathyroid, osteoporotic, and normal women. Journal of Bone and Mineral Research, 1995, 10, 1393-1399.	3.1	127
58	Comparative assessment of bone mineral density of the forearm using single photon and dual X-ray absorptiometry. Calcified Tissue International, 1992, 51, 352-355.	1.5	25